COST-EFFECTIVENESS OF IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN ENGLAND

被引：0
|
作者：
Hassan, F. [1 ]
Peng, S. [2 ]
Dorman, E. [2 ]
Sorensen, S. [2 ]
Thompson, G. [1 ]
Lee, J. [1 ]
机构：
[1] Janssen UK, High Wycombe, Bucks, England
[2] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.246
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN163
引用
收藏
页码：A441 / A441
页数：1
相关论文
共 50 条
  • [41] A SCOTLAND BASED COST-EFFECTIVENESS ANALYSIS OF IDELALISIB (ZYDELIG®) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF ADULTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA CLL)
    Kumar, G.
    Morton, T. D.
    Padhiar, A.
    Marsh, R.
    Perard, R.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [42] TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel in Combination With Ibrutinib for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 18 - 19
  • [43] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [44] Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Davids, Matthew S.
    Chang, Julie
    Ma, Shuo
    Biondo, Juliana
    Mobasher, Mehrdad
    Mun, Yong
    Mato, Anthony R.
    BLOOD, 2018, 132
  • [45] Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients
    Solman, Isabelle G.
    Taylor, Marlene
    You, Hana
    O'Brien, Susan M.
    Mulligan, Stephen P.
    Byrd, John C.
    Dean, James P.
    James, Danelle F.
    Mongan, Ann
    BLOOD, 2018, 132
  • [46] Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients
    Palma, Marzia
    Krstic, Aleksandra
    Berglof, Anna
    Wang, Qing
    Blomberg, Emelie
    Meinke, Stephan
    Kamali-Moghaddam, Masood
    Shen, Qiujin
    Jaremko, Georg
    Lundin, Jeanette
    Kimby, Eva
    Hoglund, Petter
    Mansson, Robert
    Osterborg, Anders
    Smith, Edvard
    BLOOD, 2016, 128 (22)
  • [47] Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia
    Hampel, Paul J.
    Rabe, Kari G.
    Call, Timothy G.
    Ding, Wei
    Leis, Jose F.
    Kenderian, Saad S.
    Muchtar, Eli
    Wang, Yucai
    Koehler, Amber B.
    Parrondo, Ricardo
    Schwager, Susan M.
    Shi, Min
    Braggio, Esteban
    Slager, Susan L.
    Kay, Neil E.
    Parikh, Sameer A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 239 - 244
  • [48] CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL)
    Rawstron, AC
    Davies, FE
    Evans, PA
    Jamil, A
    Galvin, MC
    Haynes, AP
    Hale, G
    Morgan, GJ
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 46 - 46
  • [49] Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?
    Jyani, Gaurav
    Gupta, Nidhi
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 42
  • [50] CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL).
    Rawstron, AC
    Davies, FE
    Evans, P
    Morgan, GJ
    Jamil, A
    Galvin, MC
    Haynes, AP
    Hale, G
    Hillmen, P
    BLOOD, 1997, 90 (10) : 2356 - 2356
12345